FDA Cites Clinical Investigator In Six Trials Of Three Cystic Fibrosis Drugs

FDA's oversight of clinical trials is becoming an increasingly significant factor in regulatory delays for some products, and a recent warning letter could have a very broad impact: it cites a clinical investigator for six trials related to three separate NDAs